Clinical Trials Logo

Diabetic Macular Edema (DME) clinical trials

View clinical trials related to Diabetic Macular Edema (DME).

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05989126 Active, not recruiting - Clinical trials for Diabetic Macular Edema (DME)

Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

Start date: April 15, 2024
Phase: Phase 3
Study type: Interventional

Regeneron Pharmaceuticals developed a single-dose pre-filled syringe (PFS) to deliver 8 mg aflibercept. The PFS is a convenient device that contains the study medication that will be injected in your study eye. A PFS offers a sterile, single dose of study drug within the syringe; this eliminates the need for the retina specialist to prepare the injection syringe from a separate vial. This Phase IIIb study is focused on patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (nAMD). The main aim of the study is to evaluate if the 8 mg aflibercept PFS allows for successful preparation and administration of 8 mg aflibercept by retina specialists. The study will also assess the safety of 8 mg aflibercept PFS use. Regeneron will use the information from the study to better understand if the PFS can be used safely and effectively by retina specialists to administer 8 mg aflibercept.

NCT ID: NCT04543331 Active, not recruiting - Clinical trials for Diabetic Macular Edema (DME)

Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema

BLUE SKY
Start date: November 5, 2020
Phase:
Study type: Observational

This study is a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC. An observational study design, without a strict, mandated visit schedule or mandated treatment regimen was chosen as the most appropriate to collect available data in a real life setting. For that reason, this NIS does not impose a therapy protocol, diagnostic/therapeutic procedure or a visit schedule. The diagnostic or monitoring procedures are only those ordinarily applied to the therapeutic strategy and to routine clinical care and will take place as per investigator's discretion. This includes e.g. visit frequency, injection frequency and types of assessments performed - only data from routine medical practice will be collected as part of the study.

NCT ID: NCT03635814 Active, not recruiting - Clinical trials for Diabetic Macular Edema(DME)

The Study to YD312 Tablet in Patients With Diabetic Macular Edema

Start date: October 19, 2017
Phase: Phase 2
Study type: Interventional

This study objectives is to evaluate the efficacy of YD312 to improve visual acuity in patients with diabetic macular edema (DME) compared to placebo and determine optimal dose of phase 2b study.